| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Windaus ketone functions primarily as a vitamin D (VD) synthesis inhibitor/blocker. It is not a direct receptor ligand but rather a chemical intermediate that can be used to study the steric and electronic requirements for vitamin D biosynthesis. It targets the vitamin D synthetic pathway by acting as a precursor analog.
|
|---|---|
| ln Vitro |
The in vitro activity of Windaus ketone is largely its role as a chemical tool in organic synthesis. It does not possess direct biological activity as a drug, but is used to validate synthetic routes and as an intermediate to produce biologically active vitamin D metabolites and steroids.
|
| ln Vivo |
In vivo activity is not applicable for this compound. It serves as a synthetic intermediate and is not administered directly to animals for primary pharmacodynamic evaluation. Any biological effects of its derivatives would be assessed separately after incorporation into larger steroid structures.
|
| Enzyme Assay |
Windaus ketone is primarily analyzed using non-cellular analytical chemistry techniques such as HPLC and GC-MS. A typical protocol involves dissolving the sample in an organic solvent (e.g., methanol or hexane), injecting onto a C18 reverse-phase HPLC column, and detecting using UV absorbance at 210-254 nm or mass spectrometry to confirm purity and identity.
|
| Cell Assay |
Windaus ketone is not typically tested in cellular assays as it is a synthetic building block, not a drug. However, cell-based assays can be performed using vitamin D-sensitive cell lines (e.g., HL-60 leukemia cells) where vitamin D metabolites synthesized from Windaus ketone are tested for their ability to induce cell differentiation or regulate gene expression (e.g., CYP24A1).
|
| Animal Protocol |
In vivo animal studies using Windaus ketone itself are not standard. Instead, fully synthesized vitamin D derivatives prepared using Windaus ketone as an intermediate are tested in mouse or rat models of hypocalcemia or osteoporosis. The intermediate is administered to animals only for metabolic tracing or chemical derivatization purposes, not for direct efficacy testing.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Windaus ketone are not characterized as it is not a therapeutic candidate. As a lipophilic, low molecular weight (276.46) ketone, it is expected to be rapidly absorbed and metabolized if administered systemically. It is typically handled as a chemical intermediate and stored at 2-8degC or -20degC for long-term storage.
|
| Toxicity/Toxicokinetics |
Windaus ketone is classified as a research chemical, not a drug. It is not intended for human consumption. The material safety data sheet (MSDS) indicates it should be handled with standard laboratory safety precautions to avoid skin and eye contact. No specific acute or chronic toxicity data has been reported for this substance alone.
|
| References |
[1]. Kiyofumi Wanibuchi, et al. Indene Compounds Synthetically Derived from Vitamin D Have Selective Antibacterial Action on Helicobacter pylori. Lipids. 2018 Apr;53(4):393-401.
|
| Additional Infomation |
Windaus ketone is also known as Windaus and Grundmann‘s C19 ketone. Its IUPAC name is (1R,3aR,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-one. It is an important historical compound in organic chemistry and is used by researchers in the synthesis of vitamin D analogues. It has no FDA approval or clinical trial status.
|
| Molecular Formula |
C19H32O
|
|---|---|
| Molecular Weight |
276.46
|
| Exact Mass |
276.245
|
| CAS # |
55812-80-1
|
| PubChem CID |
11065713
|
| Appearance |
Colorless to light yellow oil
|
| LogP |
5.256
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
381
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]2C(=O)CCC[C@]12C
|
| InChi Key |
VJIOBQLKFJUZJB-IBOOZMTFSA-N
|
| InChi Code |
InChI=1S/C19H32O/c1-13(2)14(3)8-9-15(4)16-10-11-17-18(20)7-6-12-19(16,17)5/h8-9,13-17H,6-7,10-12H2,1-5H3/b9-8+/t14-,15+,16+,17-,19+/m0/s1
|
| Chemical Name |
(1R,3aR,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6172 mL | 18.0858 mL | 36.1716 mL | |
| 5 mM | 0.7234 mL | 3.6172 mL | 7.2343 mL | |
| 10 mM | 0.3617 mL | 1.8086 mL | 3.6172 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
